Notice of Proposed Sale · 144
Candel Therapeutics, Inc.
CADLNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- CANDEL THERAPEUTICS, INC.
- Issuer CIK
- 0001841387
- SEC file number
- 001-40629
- Phone
- 6179165445
- Person for whose account securities are to be sold
- SESHU TYAGARAJAN
- Relationships to issuer
- Officer
- Street
- 117 Kendrick St, Suite 450
- City
- Needham
- State / country code
- MA
- Postal code
- 02494
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 7,000 | 82,040.00 | 76,518,565 | 08/17/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 01/07/2025 | Restricted Stock Units | Issuer | 7,000 | N | 01/07/2025 | N/A |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| 10b5-1 Sales for SESHU P TYAGARAJAN | Common | 06/29/2026 | 7,000 | 70,151.20 |
Seller — prior-sale row 1, entry 1
- Name
- 10b5-1 Sales for SESHU P TYAGARAJAN
- Street
- 117 Kendrick St, Suite 450
- City
- Needham
- State / country code
- MA
- Postal code
- 02494
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
The securities to be sold were acquired upon the vesting of restricted stock units during the period of 1/7/2025 through 1/14/2025.
Notice signature
- Notice date
- 08/17/2026
- Signed
- /s/ Seshu Tyagarajan
- Plan adoption dates
- 03/16/2026
Company context
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene) is the lead product candidate from the adenovirus platform. The Company completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA) and published in The Lancet Oncology. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the